Iberdomide PDUFA Date (Bristol Myers Squibb)

Name: FDA PDUFA Decision: Iberdomide
Start: 2026-08-17

FDA PDUFA decision date for Iberdomide is August 17, 2026. Developed by Bristol Myers Squibb. Indication: Relapsed/refractory multiple myeloma. Current status: Approved.

Indication

Relapsed/refractory multiple myeloma

Regulatory details

Company: Bristol Myers Squibb
Therapeutic area: Oncology
Application type: NDA
Review type: Standard
PDUFA date: 2026-08-17
Outcome: Approved

Iberdomide PDUFA Date — Bristol Myers Squibb